IMM vs. HVO, ORPH, REDX, ETX, SBTX, HEMO, COS, C4XD, DDDD, and FUM
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include hVIVO (HVO), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Hemogenyx Pharmaceuticals (HEMO), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Futura Medical (FUM). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
hVIVO (LON:HVO) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
ImmuPharma has a net margin of 3,519.56% compared to hVIVO's net margin of 25.96%. hVIVO's return on equity of 47.93% beat ImmuPharma's return on equity.
4.6% of hVIVO shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 4.4% of hVIVO shares are owned by company insiders. Comparatively, 8.1% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
hVIVO has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.
hVIVO has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
hVIVO presently has a consensus price target of GBX 28, indicating a potential upside of 187.15%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts plainly believe hVIVO is more favorable than ImmuPharma.
In the previous week, ImmuPharma had 78 more articles in the media than hVIVO. MarketBeat recorded 80 mentions for ImmuPharma and 2 mentions for hVIVO. hVIVO's average media sentiment score of 0.37 beat ImmuPharma's score of 0.27 indicating that hVIVO is being referred to more favorably in the media.
Summary
hVIVO beats ImmuPharma on 10 of the 15 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 9/17/2025 by MarketBeat.com Staff
